Literature DB >> 21940634

Osteopontin signals through calcium and nuclear factor of activated T cells (NFAT) in osteoclasts: a novel RGD-dependent pathway promoting cell survival.

Natsuko Tanabe1, Benjamin D Wheal, Jiyun Kwon, Hong H Chen, Ryan P P Shugg, Stephen M Sims, Harvey A Goldberg, S Jeffrey Dixon.   

Abstract

Osteopontin (OPN), an integrin-binding extracellular matrix glycoprotein, enhances osteoclast activity; however, its mechanisms of action are elusive. The Ca(2+)-dependent transcription factor NFATc1 is essential for osteoclast differentiation. We assessed the effects of OPN on NFATc1, which translocates to nuclei upon activation. Osteoclasts from neonatal rabbits and rats were plated on coverslips, uncoated or coated with OPN or bovine albumin. OPN enhanced the proportion of osteoclasts exhibiting nuclear NFATc1. An RGD-containing, integrin-blocking peptide prevented the translocation of NFATc1 induced by OPN. Moreover, mutant OPN lacking RGD failed to induce translocation of NFATc1. Thus, activation of NFATc1 is dependent on integrin binding through RGD. Using fluorescence imaging, OPN was found to increase the proportion of osteoclasts exhibiting transient elevations in cytosolic Ca(2+) (oscillations). OPN also enhanced osteoclast survival. The intracellular Ca(2+) chelator 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) suppressed Ca(2+) oscillations and inhibited increases in NFATc1 translocation and survival induced by OPN. Furthermore, a specific, cell-permeable peptide inhibitor of NFAT activation blocked the effects of OPN on NFATc1 translocation and osteoclast survival. This is the first demonstration that OPN activates NFATc1 and enhances osteoclast survival through a Ca(2+)-NFAT-dependent pathway. Increased NFATc1 activity and enhanced osteoclast survival may account for the stimulatory effects of OPN on osteoclast function in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940634      PMCID: PMC3220590          DOI: 10.1074/jbc.M111.295048

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

Review 1.  Molecular mechanism of the life and death of the osteoclast.

Authors:  Sakae Tanaka; Tsuyoshi Miyazaki; Akira Fukuda; Toru Akiyama; Yuho Kadono; Hidetoshi Wakeyama; Shinjiro Kono; Shinya Hoshikawa; Masaki Nakamura; Yasushi Ohshima; Atsuhiko Hikita; Ichiro Nakamura; Kozo Nakamura
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

2.  Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.

Authors:  A Miyauchi; J Alvarez; E M Greenfield; A Teti; M Grano; S Colucci; A Zambonin-Zallone; F P Ross; S L Teitelbaum; D Cheresh
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

3.  Crystallization of calcium oxalates is controlled by molecular hydrophilicity and specific polyanion-crystal interactions.

Authors:  Bernd Grohe; Adam Taller; Peter L Vincent; Long D Tieu; Kem A Rogers; Alexander Heiss; Esben S Sørensen; Silvia Mittler; Harvey A Goldberg; Graeme K Hunter
Journal:  Langmuir       Date:  2009-10-06       Impact factor: 3.882

4.  Structural determinants of calcium signaling by RGD peptides in rat osteoclasts: integrin-dependent and -independent actions.

Authors:  G Shankar; T R Gadek; D J Burdick; I Davison; W T Mason; M A Horton
Journal:  Exp Cell Res       Date:  1995-08       Impact factor: 3.905

5.  Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.

Authors:  H Shiraga; W Min; W J VanDusen; M D Clayman; D Miner; C H Terrell; J R Sherbotie; J W Foreman; C Przysiecki; E G Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 6.  Transcription factors of the NFAT family: regulation and function.

Authors:  A Rao; C Luo; P G Hogan
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice.

Authors:  Andre Paes Batista da Silva; Richard P Ellen; Esben S Sørensen; Harvey A Goldberg; Ron Zohar; Jaro Sodek
Journal:  Lab Invest       Date:  2009-08-10       Impact factor: 5.662

Review 8.  Control of osteopontin signaling and function by post-translational phosphorylation and protein folding.

Authors:  Christian C Kazanecki; Dana J Uzwiak; David T Denhardt
Journal:  J Cell Biochem       Date:  2007-11-01       Impact factor: 4.429

9.  Expression, signaling, and function of P2X7 receptors in bone.

Authors:  Matthew W Grol; Nattapon Panupinthu; Jasminka Korcok; Stephen M Sims; S Jeffrey Dixon
Journal:  Purinergic Signal       Date:  2009-02-18       Impact factor: 3.765

10.  Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.

Authors:  M Ishijima; S R Rittling; T Yamashita; K Tsuji; H Kurosawa; A Nifuji; D T Denhardt; M Noda
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  18 in total

Review 1.  A potential role for integrin signaling in mechanoelectrical feedback.

Authors:  Borna E Dabiri; Hyungsuk Lee; Kevin Kit Parker
Journal:  Prog Biophys Mol Biol       Date:  2012-07-20       Impact factor: 3.667

Review 2.  Integrins and integrin-associated proteins in the cardiac myocyte.

Authors:  Sharon Israeli-Rosenberg; Ana Maria Manso; Hideshi Okada; Robert S Ross
Journal:  Circ Res       Date:  2014-01-31       Impact factor: 17.367

3.  Bone biology-related gingival transcriptome in ageing and periodontitis in non-human primates.

Authors:  Subramanya N Pandruvada; Octavio A Gonzalez; Sreenatha Kirakodu; Sudha Gudhimella; Arnold J Stromberg; Jeffrey L Ebersole; Luis Orraca; Janis Gonzalez-Martinez; Michael J Novak; Sarandeep S Huja
Journal:  J Clin Periodontol       Date:  2016-04-06       Impact factor: 8.728

4.  5-Azacytidine-induced protein 2 (AZI2) regulates bone mass by fine-tuning osteoclast survival.

Authors:  Kenta Maruyama; Masahiro Fukasaka; Satoshi Uematsu; Osamu Takeuchi; Takeshi Kondo; Tatsuya Saitoh; Mikaël M Martino; Shizuo Akira
Journal:  J Biol Chem       Date:  2015-02-17       Impact factor: 5.157

5.  SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.

Authors:  Tomoyuki Mukai; Shu Ishida; Remi Ishikawa; Teruhito Yoshitaka; Mizuho Kittaka; Richard Gallant; Yi-Ling Lin; Robert Rottapel; Marco Brotto; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

Review 6.  The functions and applications of RGD in tumor therapy and tissue engineering.

Authors:  Fen Wang; Yuanyuan Li; Yingqiang Shen; Anming Wang; Shuling Wang; Tian Xie
Journal:  Int J Mol Sci       Date:  2013-06-27       Impact factor: 5.923

7.  SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.

Authors:  Tomoyuki Mukai; Richard Gallant; Shu Ishida; Teruhito Yoshitaka; Mizuho Kittaka; Keiichiro Nishida; David A Fox; Yoshitaka Morita; Yasuyoshi Ueki
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

8.  Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.

Authors:  Johanna Eriksson; Vadim Le Joncour; Pirjo Nummela; Tiina Jahkola; Susanna Virolainen; Pirjo Laakkonen; Olli Saksela; Erkki Hölttä
Journal:  Oncotarget       Date:  2016-03-22

9.  CD44 deficiency inhibits unloading-induced cortical bone loss through downregulation of osteoclast activity.

Authors:  Yuheng Li; Guohui Zhong; Weijia Sun; Chengyang Zhao; Pengfei Zhang; Jinping Song; Dingsheng Zhao; Xiaoyan Jin; Qi Li; Shukuan Ling; Yingxian Li
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

10.  High fat diet increases melanoma cell growth in the bone marrow by inducing osteopontin and interleukin 6.

Authors:  Guang-Liang Chen; Yubin Luo; Daniel Eriksson; Xianyi Meng; Cheng Qian; Tobias Bäuerle; Xiao-Xiang Chen; Georg Schett; Aline Bozec
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.